FDA and Patent Strategies for Life Sciences Innovators

02 Dec 2021 12:00 p.m. - 01:00 p.m. EST

Life sciences innovators at all stages seek patent protection to limit market competition and, in some cases, attract further investment. Careful IP planning is especially important in the life sciences, with many companies relying on a handful of patents to protect their high-value products.

It is essential that companies pay close attention to the interrelationship between patent and US Food and Drug Administration (FDA) regulatory considerations to protect their most valuable assets for the long term.

Morrison & Forester is a proud sponsor of LSPN Connect. Join attorneys Brigid Bondoc and Lisa Silverman on Thursday, December 2, at 12pm EST for a LSPN Connect session, “FDA and Patent Strategies for Life Sciences Innovators”.

This webinar will explore:


  • Strategies for obtaining strong patent protection for small molecule and biologics drugs
  • Maximizing patent term through Patent Term Adjustment (PTA) and Patent Term Extension (PTE)
  • FDA regulatory exclusivities
  • Orange Book vs Purple Book patent listings
  • Due diligence considerations

If you’re not already a member of LSPN Connect, you can register for a Taster Ticket, which gives you complimentary access to 3 sessions.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.